The current status of S-100B as a biomarker in melanoma

European Journal of Surgical Oncology

Volumn 38, Issue 4, 2012, Pages 281-285

  Kruijff, S ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Melanoma; S 100B

Indexed keywords

BEVACIZUMAB; IPILIMUMAB; LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER; VEMURAFENIB;

BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL HETEROGENEITY; DISSEMINATED CANCER; HUMAN; LIVER METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MORBIDITY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SENTINEL LYMPH NODE BIOPSY; STRATIFIED SAMPLE; SYSTEMIC THERAPY; TUMOR NECROSIS;

HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857921453     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.12.005     Document Type: Review

References (36)

1. L.M. Hollestein, S.A. van den Akker, and T. Nijsten Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989 Ann Oncol 2011 May 4 [Epub ahead of print]
2. E. De Vries, S. Houterman, and M.L. Janssen-Heijnen Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of the Netherlands Ann Oncol 18 2007 1110 1116 (Pubitemid 47050504)
3. M.J. Reinhardt Cutaneous melanoma Recent Results Cancer Res 170 2008 151 157
4. M.J. Sladden, C. Balch, and D.A. Barzilai Surgical excision margins for primary cutaneous melanoma Cochrane Database Syst Rev 4 2009 CD004835
5. C.M. Balch, J.E. Greshenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
6. C. Garbe, and T.K. Eigentler Diagnosis and treatment of cutaneous melanoma: state of the art 2006 Melanoma Res 17 2007 117 127 (Pubitemid 46673905)
7. S. Siesling, O. Visser, and J.A. van Dijck Trends in the incidence and death from cancer from 1989-2003 in The Netherlands Ned Tijdschr Geneeskd 150 2006 2490 2496
8. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma New Engl J Med 363 2010 711 723
9. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
10. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
11. J.F. Keuren, C.M. Thomas, J.M. Bonfrr, C.G. Sweep, and J.G. Boonstra Asesment of tumor markers in clinical practice Ned Tijdschr Geneeskd 153 2009 A617
12. S. Kruijff, E. Bastiaannet, and A.H. Brouwers The use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma Ann Surg Oncol 2011 [published online 23 august 2011]
13. B.R. Hill, and C. Levi Elevation of a serum component in neoplastic disease Cancer Res 14 1954 513 515
14. S. Kruijff, E. Bastiaannet, and A.C. Muller-Kobold S-100B concentrations predict disease-free survival in stage III melanoma patients Ann Surg Oncol 16 2009 3455 3462
15. B.W. Moore A soluble protein characteristic of the nervous system Biochem Biophys Res Commun 19 1965 739 744
16. L.H. Smit, C.M. Korse, and A.A. Hart Normal values of S-100B predict prolonged survival for stage IV melanoma patients Eur J Cancer 41 2005 386 392 (Pubitemid 40187209)
17. G. Ghanem, B. Loir, and R. Morandini On the release and halflife of S-100B protein in the peripheral blood of melanoma patients Int J Cancer 94 2001 586 590
18. E.D. Martenson, L.O. Hansson, and B. Nilsson Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma J Clin Oncol 19 2001 824 831 (Pubitemid 32119098)
19. M.Q. Mohammed, H.D. Abraha, and R.A. Sherwood S. Serum S100 beta protein as a marker of disease activity in patients with malignant melanoma Med Oncol 18 2001 109 120 (Pubitemid 32929483)
20. J. Klode, J. Dissmond, and S. Grabbe Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on cancer stages I and II Dermatol Surg 36 2010 439 445
21. F. Egberts, A. Momkvist, J.H. Egberts, K.C. Kaehler, and A. Hauschild Serum S-100B and LDH are not useful in predicting the sentinel node status in melanoma patients Anticancer Res 30 2010 1799 1805
22. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel node biopsy and immediate lymphadenectomy for occult metastases versus nodal observation and delayed lymphadenectomy for nodal recurrence Ann Surg Oncol 17 Suppl. 1 2010 S22 S23 (Abstract 53)
23. K. Havenga, D.C. Cobben, and W.J. Oyen Fluorodeoxyglucose-positron Emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma Eur J Surg Oncol 29 2003 662 664 (Pubitemid 37236287)
24. E. Bastiaannet, J.C. Beukema, and H.J. Hoekstra Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications Cancer Treat Rev 31 2005 18 26 (Pubitemid 40246987)
25. M.A. Henderson, B. Burmeister, and J.F. Thompson Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy; Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01) J Clin Oncol 27 2009 18s, 2009 (suppl; abstr LBA9084)
26. C.M. Balch, J.E. Gershenwald, and S. Soong Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2010 2452 2459
27. A.A. Tarhini, J. Stuckert, and S. Lee Prognostic significance of serum S-100B surgically resected melanoma patients participating in intergroup trial ECOG 1694 J Clin Oncol. 27 2008 38 44
28. M.G. Bouwhuis, S. Suciu, and W. Kruit Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952 Eur J Cancer 47 2011 361 368
29. S. Kruijff, E. Bastiaannet, M.J. Speijers, I.P. Kema, R.J. Van Ginkel, and H.J. Hoekstra S-100B concentrations predict disease specific survival in AJCC stage III melanoma patients Ann Surg Oncol 18 Suppl. 1 2011 S1 S144 P227
30. A.P. Hamberg, C.M. Korse, J.M. Bonfrer, and G.C. de Gast Serum S-100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res 13 2003 45 49 (Pubitemid 36269813)
31. H.M. Kluger, K. Hoyt, and A. Bacchiocchi Plasma markers for identifying patients with metastatic melanoma Clin Cancer Res 15 2011 2417 2425
32. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
33. C. Garbe, K. Peris, and A. Hauschild Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline Eur. J Cancer 46 2010 270 283
34. S. Mocellin, G. Zavagno, and D. Niiti The prognostic value of serum S-100B in patients with cutaneous melanoma: a meta-analysis Int J Cancer 123 2008 2370 2376
35. Jing Lin, Qingyuan Yang, and P.T. Wilder The calcium-binding protein S-100B Down-regulates p53 and apoptosis in malignant melanoma J Biol Chem 27 2010 27487 27498
36. J. Markowitz, A.D. Mackerell Jr., F. Carrier, T.H. Charpentier, and D.J. Weber Design of inhibitors for S-100B Curr Top Med Chem 5 2005 1093 1108